Physician profile
David Luebbert
NPI 1922419464
$1,792.26
in general payments reported to CMS, 2019-2025
22 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2023: $45.68 · 2024: $512 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $328.42 | 2019-2025 | |
| Novo Nordisk INC | $256.97 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $253.14 | 2023-2025 | |
| Exact Sciences Corporation | $181.93 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $152.17 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $119.86 | 2023-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $106.85 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $48.95 | 2019 | |
| Corcept Therapeutics | $44.98 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $37.96 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.99 | 2023-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.41 | 2025 | Caplyta |
| Amgen INC. | $28.51 | 2025 | Evenity |
| Hologic Sales and Service, LLC | $24.00 | 2025 | Aptima, Thinprep 2000 Processor |
| Philips North America LLC | $22.93 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $20.88 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $19.80 | 2025 | Neffy |
| Sanofi Pasteur INC. | $19.05 | 2025 | |
| Sumitomo Pharma America, INC. | $16.74 | 2025 | Gemtesa |
| Nevro Corp. | $14.44 | 2024 | Senza |
| Seqirus USA INC | $13.69 | 2025 | Flucelvax, Fluad |
| Tolmar, INC. | $13.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Luebbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.